Phase I, Open-label, Dose Escalation of AZD4877 in Hematologic Malignancies

Stopped early · Phase 1

Conditions studied: Lymphoma

In brief

The primary purpose of this study is to find out what the maximum tolerated dose is for an experimental drug called AZD4877 based on the side effects experienced by patients that receive AZD4877 on a weekly basis in these diseases.

Key facts

Study ID

NCT00460460

Run by

AstraZeneca

People needed

75

Starts

2007-03-01

Expected to finish

2007-08-01

Last updated by the study team

2011-01-25

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients with AML, a certain type of ALL, NHL and MM
• certain types of cancer of the lymph nodes
• certain types of leukemias (blood cancers)
• disease has or will fail with other treatments
• relatively good overall health other than your cancer

You may not qualify if…

• poor bone marrow function (not producing enough blood cells)
• serious heart conditions
• poor liver or kidney function

Where it is running

• Research site — Buffalo, New York, United States
• Research Site — New York, New York, United States
• Research Site — Toronto, Ontario, Canada

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.